Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2023 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

ALPHARETTA, Ga., April 27, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
April 19, 2023 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

ALPHARETTA, Ga., April 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
April 18, 2023 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

- Multiple U.S. Clinical Sites to Begin Enrolling ODYSSEY Participants This Quarter - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- Clearside...
April 12, 2023 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference

ALPHARETTA, Ga., April 12, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
April 05, 2023 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians

ALPHARETTA, Ga., April 05, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
March 09, 2023 16:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

- Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety...
February 23, 2023 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023

ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
February 21, 2023 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings

- CLS-AX OASIS Results Show Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - SCS Microinjector® Featured in Favorable Data...
February 07, 2023 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023

ALPHARETTA, Ga, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
February 06, 2023 07:30 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Leadership Team Update

ALPHARETTA, Ga., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right